Medivation’s business is built on the identification and rapid development of product candidates that have the potential to improve the standard of care in human diseases. Our current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs—Alzheimer’s disease, Huntington disease and castration-resistant prostate cancer. We intend to build and maintain a portfolio of multiple development programs at all times.

Drug/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status
Dimebon (latrepirdine)
Alzheimer's Disease
CONNECTION
study in patients with mild-to-moderate disease
  • First pivotal trial successfully completed
  • Second pivotal trial underway; completion of enrollment expected in 2009
  • Additional trials planned in patients with moderate-to-severe disease and those taking cholinesterase inhibitors
CONCERT
study in patients with mild-to-moderate disease on donepezil
Safety Trial
CONSTELLATION
study in patients with moderate-to-severe disease on memantine
CONTACT
study in patients with moderate-to-severe disease on donepezil
Huntington Disease
  • Phase 2 trial completed, reporting topline positive safety and efficacy results
  • Next trial to start in 2009
HORIZON
study to evaluate cognition

 

 

Drug/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status
MDV3100
Castration-Resistant Prostate Cancer
  • Phase 1-2 clinical trial ongoing with positive initial data announced
  • Phase 3 trial to start in 2009
AFFIRM
study currently enrolling men previously treated with docetaxel-based chemotherapy

 

 
Print E-mail  
Medivation © 2010